

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/P3AABA7F4F4EEN.html>

Date: August 2022

Pages: 218

Price: US\$ 2,000.00 (Single User License)

ID: P3AABA7F4F4EEN

Abstracts

Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) - Drugs In Development, 2022, provides an overview of the Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline landscape.

Peripheral vascular disease (PVD) refers to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh or calf muscles after activity, such as walking or climbing stairs (intermittent claudication), leg numbness or weakness, coldness in lower leg or foot, especially when compared with the other side, sores on toes, feet or legs that won't heal, slower growth of toenails and erectile dysfunction in men.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for

Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 10, 11, 3, 17 and 4 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular).

The pipeline guide reviews pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics
Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics
Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies
Involved in Therapeutics Development

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Drug Profiles

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant
Projects

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued
Products

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Product
Development Milestones

Featured News & Press Releases

Jun 28, 2022: JanOne announces an improved formulation of JAN101

Jun 07, 2022: JanOne announces the issuance of U.S. patent covering a method of
improving nerve function using JAN101

May 10, 2022: Hemostemix announces its intellectual property is back home

Jul 22, 2021: JanOne selects CPC Clinical Research as trial manager for phase 2b
study of JAN101 for peripheral artery disease patients

Feb 10, 2021: Sanifit granted orphan drug designation by the FDA for SNF472 for the
treatment of peripheral arterial disease in patients with end-stage kidney disease

Aug 26, 2020: JanOne advances its potential peripheral artery disease and Covid-19
vascular inflammation treatment towards trial readiness

Aug 21, 2020: JanOne to host telebriefing to discuss drug candidate JAN101 for

treatment of peripheral artery disease (PAD) and potential applications for COVID-19 vascular complications

Aug 19, 2020: JanOne to present at The LD 500 Virtual Conference

Aug 11, 2020: JanOne completes stable formulation of JAN101 in preparation for its first GMP manufacturing batch to support upcoming clinical trials

Aug 06, 2020: JanOne engages CATO SMS, a world-leading CRO, to assist in the development of JAN101 to treat COVID-19 vascular complications

Aug 04, 2020: JanOne changes internal drug candidate name from TV1001SR to JAN101

Jul 21, 2020: JanOne receives FDA authorization for transfer of Investigational New Drug (IND) application for its Sodium Nitrite tablets

Jul 20, 2020: Sanifit to start new clinical development program of SNF472 in End Stage Kidney Disease patients with Peripheral Artery Disease

Jul 26, 2018: Foresee Pharmaceuticals Announces Results from a Phase 1 Clinical Study, Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile of FP-045, a Potent ALDH2 Activator

Jan 22, 2018: AnGes Submits Application for Marketing Approval to PMDA for HGF gene therapy for Critical Limb Ischemia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Peripheral Arterial Disease (PAD)/
Peripheral Vascular Disease (PVD), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant
Projects, 2022

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant
Projects, 2022 (Contd..1)

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant
Projects, 2022 (Contd..2)

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued
Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Peripheral Arterial Disease (PAD)/
Peripheral Vascular Disease (PVD), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/P3AABA7F4F4EEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P3AABA7F4F4EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970